

Published in final edited form as:

Wiley Interdiscip Rev RNA. 2012 ; 3(5): 601–616. doi:10.1002/wrna.1120.

Potential Pitfalls in microRNA Profiling

Pauline Chugh and Dirk P. Dittmer

Abstract

MicroRNAs (miRNAs) are small, noncoding RNAs that post-transcriptionally influence a wide range of cellular processes such as the host response to viral infection, innate immunity, cell cycle progression, migration and apoptosis through the inhibition of target mRNA translation. Due to the growing number of microRNAs and identification of their functional roles, miRNA profiling of many different sample types has become more expansive, especially with relevance to disease signatures. Here, we address some of the advantages and potential pitfalls of the currently available methods for miRNA expression profiling. Some of the topics discussed include isomiRNAs, comparison of different profiling platforms, normalization strategies and issues with regard to sample preparation and experimental analyses.

Keywords

miRNA; profiling; isomiRNAs; qPCR; Next Generation sequencing; normalization

MiRNAs are a class of small, noncoding RNAs that have emerged as a novel and rapidly expanding area of interest in disease research. This is in large part due to their ability to fine tune expression of a vast number of target genes through mRNA degradation or translational repression. Binding of mature miRNAs (approximately 19-25 nt) to target genes through the 5' nucleotides 2-8, termed the "seed sequence", allows each of these small RNAs to impact the expression of hundreds of downstream genes. These and other rules derived from bioinformatics experiments capture the majority of cases, but not all. For instance, examples exist where nucleotides outside the seed sequence contribute to target recognition¹⁻³. The size of the miRNA is variable with experimentally confirmed extremes of 16 nt and 35 nt in length⁴⁻⁷. Lastly, miRNAs are subject to mutation and selection and single nucleotide polymorphisms in mature and precursor miRNAs have been described, which can modulate targeting, processing and expression⁸⁻¹⁰. Any study of miRNAs must start with an accurate and detailed accounting of the species and expression levels of the miRNA collection in the cell of interest.

In addition to cellular microRNAs, several viruses including the herpesvirus family can encode miRNAs to aid in the establishment of viral latency and persistence, immune evasion, cellular proliferation and tumor progression¹¹⁻¹⁶. MiRNAs encoded by the herpesviruses are also involved in controlling the molecular switch of the viral lifecycle between latency and lytic replication and reactivation^{11, 12, 17-23}. Several groups have examined changes in the cellular miRNA repertoire following acute viral infection, which has piqued even more interest in the field of miRNA profiling^{8-12, 17-36}.

Profiling of the MiRNA Repertoire

MiRNA profiling can provide useful information on the pathogenesis of many different diseases. Identification of novel miRNAs can reveal new levels of gene regulation associated with a specific disease. Profiling of host miRNAs at different stages of cancer, for example, can give insight into potential biomarkers associated with tumor progression, metastasis and angiogenesis^{11, 12, 35, 37-40}. In some cases, altered expression of a few key

miRNAs can separate groups of patients into clinically relevant classes. Moreover, miRNAs are relatively stable and the detection of miRNAs in serum and plasma may allow miRNAs to emerge as clinically useful disease biomarkers^{27, 34-37, 41-43}. Here, we will delineate some of the broader concerns with miRNA profiling and the advantages and pitfalls of the different profiling techniques.

Overview of the miRNA maturation pathway

We start our discussion with a brief overview of the miRNA maturation pathway, since any intermediate in this pathway can be subjected to profiling and may reveal non-redundant information about the cell (Figure 1). For example, qPCR analysis of the miRNA gene locus may provide insight into deletions, amplifications or SNPs in the microRNA gene. Both primary and precursor microRNAs (pri- and pre-miRNAs) can provide information on the transcriptional regulation of microRNAs whereas profiling the more mature microRNA form can lead to insights on function, target specificity, and changes in processing and microRNA export and stability.

Specifically, each processing step has its own rate constant k , which determines the pool size and pool turnover for the next intermediate (Figure 2). The primary microRNA transcript is subject to less processing and therefore dependent on the least number of processing rates/ k values. As the microRNA matures, the number of k values with the potential to influence the pool size and turnover increases. Another factor to consider for profiling of different classes of microRNAs is that it is increasingly difficult to design specific primers for the detection of smaller targets. Depending on the diagnostic objective it may be desirable to profile the most mature, most stable pool, e.g. for tissue of origin profiling or it may be opportune to profile more immature intermediates, e.g. to interrogate the cell response to infection or drug.

Following microRNA processing, one strand of the mature miRNA is incorporated into the RNA-induced silencing complex (RISC), which can now recognize its target mRNA. Of note, not every miRNA that is expressed is loaded onto the RISC complex⁴⁴. The remaining unused strand is called the *strand or the passenger strand and is often degraded^{18, 24, 45-47}. Selection of the incorporated strand depends on the relative stability of the base pairing at the 5' end of each strand. The mature miRNA strand exhibiting weaker base pairing at its 5' end is usually selected for incorporation into the RISC^{44, 48}. However, if there is little difference in the base pairing stability, each strand may be incorporated into the complex, thus increasing the number of potential mRNA targets.

Overview of Current Profiling Methods

Quantitative real-time PCR (qPCR) is considered the gold standard of gene expression measurement. Several companies have developed qPCR-based assays for the detection of miRNA expression⁴⁹⁻⁵¹ and have increased throughput with the introduction of microfluidic array platforms, which allow one to analyze thousands of miRNAs at the same time⁵²⁻⁵⁴. This technology can also be applied to pre-miRNA and pri-miRNA profiling^{12, 40} and is typically done on total RNA. Size selection is not necessary because of the superior specificity of the primers.

Another technique for miRNA profiling is the hybridization-based glass-slide microarray⁵⁵⁻⁶⁰. Microarrays have been used extensively in the past for gene expression profiling and thus are well-optimized and robust. The main difference between mRNA and miRNAs is the small size of the target. Thus, the advantages of longer oligos (e.g. 70-mers used in many commercial mRNA slide arrays) do not exist for miRNA profiling. At least in principle, both mature and pre-miRNAs can hybridize to the target, since they contain the

same sequence. This may boost sensitivity or may require additional size selection prior to labelings if very precise measurements of mature miRNAs are needed.

Since clinical samples are often small and only a very limited amount of miRNAs can be extracted, non-specific amplification methods are of great practical value. Of course, all non-specific amplification methods may affect the linearity of the final assay. These methods are well established and commercially available for mRNAs and typically incorporate a T7 polymerase recognition site within the primer for reverse transcription⁶¹. Because miRNAs are much smaller, adding an amplification step is not trivial and is likely to introduce non-linearity into the measurement process.

The growing popularity of Next Generation Sequencing has introduced yet another technique for studying miRNA profiles. In this method, adapters are ligated to sample RNA and cDNA libraries are made and amplified by PCR. These libraries are then sequenced and the output reveals sequencing reads of varying lengths corresponding to miRNAs, which are then aligned to the reference sequence of choice. Importantly, PCR amplification of sequencing libraries can also introduce issues with linearity. Northern blots and RNase protection assays are other ways of measuring miRNA expression but are time-consuming. They require large amounts of sample input and are not suitable for high-throughput screens. For these reasons, we will not focus on these techniques in this review, although they can be used to confirm miRNA expression.

A more recent development in microRNA expression profiling is the nanotechnology-based assay for microRNA^{62, 63}. This platform eliminates some of the biases resulting from other profiling platforms because it does not require enzymatic modifications such as ligation or reverse transcription^{62, 63}. Instead, it utilizes nanopores that can detect the position and conformation of the target molecule within the pore and provides highly sensitive, quantitative data for miRNA molecules in a given sample⁶²⁻⁶⁴. For more on this profiling technique, please refer to the following reviews⁶⁴⁻⁶⁸.

Factors to Consider when Selecting a Profiling Platform

Choosing the appropriate methods for miRNA profiling can be difficult as there are many factors to consider⁶⁹. Some platforms are able to detect more drastic changes than others, due to variation in dynamic range. However, this large range of detection is not necessary if only a 2-fold change in expression is significant in the samples being analyzed. qPCR and sequencing both have broad dynamic ranges but require different amounts of sample input and runtime (Table 1). Sequencing can be helpful in determining sequence and end variation but also requires additional time and expertise in bioinformatic analysis. We estimate as much analysis time as profiling time for qPCR and microarrays and about ten-times as much analysis time for complete sequencing-based analyses. Therefore, if prior studies have narrowed the field of interest to a smaller group of interesting miRNAs, qPCR assays and microarrays may be most cost- and time-effective (Table 1). The specificity and quality of the profiling results is often more important than the sheer number of miRNAs profiled. It is advisable to choose the platform that attains the best balance between cost, precision, accuracy and sample availability for your study (Table 1).

At present, the Sanger database (<http://mirbase.org/>, release 18.0) lists 18,226 precursor miRNAs expressing 21,643 mature miRNAs from 168 different species⁴⁻⁷. Of these, over 1500 are human miRNA sequences and over 800 are derived from mouse⁴⁻⁷. A virtual database of tissue-specific expression for experimental design purposes can be found at www.microrna.org. At first glance, the ultimate goal in miRNA profiling is to obtain an accurate overall picture of the miRNA repertoire. However, the experimental design to achieve this goal is not always straightforward. First, we need to consider an important

biological property of the cellular miRNA pool. NextGen sequencing has shown that, with few exceptions, a small number (<20) of miRNAs accounts for > 80% of all cellular miRNAs⁷⁰. By an extreme example, the liver-specific microRNA miR-122 accounts for > 50% of all miRNA molecules expressed in hepatocytes³⁸. Similar results were obtained when looking at the overall expression of viral microRNAs. In KSHV infected lymphoma cells, the 23 viral miRNAs account for over 80% of all miRNA molecules³¹.

For these abundant miRNAs, a small (2-fold) change will have a significant impact on target protein levels. However, even a 10-fold change in a miRNA of low abundance (<1% of total) may not translate into a measurable biological phenotype. This shouldn't discount the importance of low abundance miRNAs completely, as less abundant miRNAs may still serve as specific biomarkers for a correlated disease phenotype. Biomarkers can be of high predictive (and commercial) value even if the functional mechanism is unknown^{27, 34, 41, 43, 53, 71-73}. Lastly, only a few miRNAs have a known biological function and validated, experimental targets. All too often, exhaustive profiling experiments yield statistically significant changes in miRNAs that are completely uncharacterized. At that point, the follow-up work to attach biological plausibility and significance to a profiling result becomes substantial. Several groups have studied the biological activity of microRNAs in terms of kinetics of the mRNA-miRNA interaction and miRNA abundance with relevance to experimental applications⁷⁴⁻⁸⁰.

Pitfalls and Concerns

One source of confusion when comparing miRNA profiling data is that they are only somewhat reproducible between different platforms and even intraplatform variation is common⁶⁹. Typically, the relative quantification of miRNA expression is similar among the various platforms and biological repeats whereas the absolute expression measurements tend to vary.

Often times the variation with regard to sample classification between profiling platforms results from the contribution of miRNAs with very low abundance. This reflects the different sensitivities of the expression profiling methods. One approach is to use rigorous thresholding, by only including the 50 most abundant miRNAs in an experiment in cross-platform comparison. Because of the biological makeup of the miRNA pool (see above), these would capture > 90% of the miRNA repertoire. A disadvantage of this approach is that it can be subject to platform-specific biases with regard to a single miRNA. For instance, in the early days of profiling by sequencing, the miRNAs were cloned prior to Sanger sequencing of libraries. Because one of the cloning steps relied on a particular restriction endonuclease, miRNAs that contained the endonuclease recognition site were never part of the library³⁰. By extrapolation, there will always be a few miRNAs that because of their particular sequence are not efficiently labeled, sequenced or amplified and thus lost to analysis.

IsomiRNAs and RNA editing

MiRNA heterogeneity and isomiRNAs—Another factor that can complicate miRNA profiling is the recent discovery of isomiRNAs⁸¹⁻⁸³. IsomiRNAs are miRNAs that display sequence variations, typically by shortening or lengthening of the 3' end. Figure 3 shows an example of the variation in miRNA length and sequence. Some have argued that shorter isomiRNAs may be miRNA degradation products but the presence of longer isomir sequences suggests otherwise^{81, 83}. A recent study identified over 3300 miRNA variants and found that in several cases, the most abundant miRNA differed from the miRBase sequence³⁹. Moreover, the dominant isomiRNA expressed can vary by tissue and sample. A comprehensive list of isomiRNAs that have been experimentally identified can be found at

<http://galas.systemsbiology.net/cgi-bin/isomir/find.pl>⁸³. This database may prove useful in determining the most abundant sequence of a particular miRNA and the degree of heterogeneity for each miRNA species⁸³. It is somewhat reassuring that in many cases, one or two isomers account for > 90% of the species and thus of the signal detected (Figure 3). The remaining variants even if extensive, are not abundant enough to contribute to the signal (Figure 3). The potential pitfall exists that in certain commercial assays the wrong isoform may be included as the sensor.

How heterogeneity arises—MiRNA sequence variations can result from post-transcriptional modifications and differential processing. Alternative processing of primary miRNA transcripts by Drosha can generate multiple pre-miRNA species and further expand the sequence heterogeneity of mature miRNAs⁸⁴. In addition, RNA editing events like deamination, 3' end processing of stable intermediates, base substitutions and 3' extensions and 5' deletions can add to the complex nature of miRNA sequence variation^{82, 85-87}. Several groups have shown that although sequencing or enzymatic errors could potentially account for some of this variation, miRNA heterogeneity is not a technical artifact but more likely generated *in vivo* through biologically relevant processes⁸⁴.

Functional consequences—One could infer that variations in the 5' end of the miRNA may drastically alter the seed sequence and target specificity. Further, variations even within the 3' end may affect the affinity at which a miRNA binds to its target^{86, 88}. miRNA sequence variations may also alter the specificity of miRNA association with different Argonaute proteins, another functional consequence of isomiRNAs and RNA editing^{82, 85}.

Potential issues with detection—MiRNA end heterogeneity can affect the consistency and accuracy of measuring miR expression levels. Since qPCR and microarrays heavily rely on the availability and accuracy of miRBase sequences for primer and probe design, mutations can lead to miRNA detection issues. One study found that as few as 1-2 nucleotide changes in the miRBase sequence from either end can drastically affect the miRNA profiling results⁸³.

In the broader picture, accumulation of miRNA expression levels can depend on the rate of transcription, processing and miRNA decay. The stability of miRNAs can be controlled by cis-acting modifications, protein complex formation and exposure to nucleases⁸⁹. When a mature miRNA is in complex--especially within the Ago/RISC complex-- its stability is greatly increased, allowing for enhanced detection of these miRNAs. A recent study showed that these miRNA/Ago complexes could be found in serum and plasma and exhibited high stability for miRNA profiling³⁷. Therefore, miRNAs that preferentially mask themselves in these ribonucleoprotein complexes may outlast others and thus could be reflected in the miRNA repertoire.

Platform-specific concerns - QPCR-based Profiling

Here, we will focus on some of the technical issues that may arise with qPCR-based profiling of miRNAs. Although much of this section is dedicated to qPCR profiling due to our experience in this area, many of the same problems are also encountered using microarrays⁹⁰.

Overall, qPCR is a popular, reliable technique for miRNA profiling because of its high sensitivity, reproducibility and large dynamic range. More recently, this method has expanded to accommodate even more high-throughput capability with the introduction of microfluidic qPCR^{52-54, 91, 92}. These methods and their smaller reaction size (down to nanoliters) provide the user with rapid, cost-effective customizable arrays that decrease

sample input and allow thousands of reactions per experimental run. qPCR-based profiling is more rapid than other platforms and accommodates a wide range of samples, from cells to formalin-fixed, paraffin-embedded (FFPE) tissues requiring limited input. qPCR assays can be easily automated using robotic systems, which reduce hands-on time significantly and decrease variation due to human pipetting error⁹³.

Preparation Methods and Specificity

qPCR profiling is highly compatible with fixed tissue samples. Even during RNA-protein crosslinking, short RNAs like miRNAs may be less affected than other RNA species due to their smaller size and high stability. However, prior to profiling, RNA sample quality should be tested by running an RNA or Agilent gel. Although RNA quality is less important when detecting miRNAs as compared with mRNAs, it can provide insight into the potential degradation of RNA, quality of the nucleic acid isolation procedure and could affect the overall outcome of the qPCR results.

Once purified RNA is obtained, the process of cDNA synthesis can introduce unexpected variation, more so than the qPCR step itself^{61, 94}. One study found that the cDNA synthesis reaction could introduce up to 100-fold variation in RT yields^{61, 95}. Introduction of errors due to secondary structure, variation in priming efficiency and properties of the RT enzyme itself can all influence the product yield from the RT reaction⁶¹.

Much of the error introduced with qPCR-based profiling is due to preferential ligation and amplification. Certain miRNAs can preferentially bind or hybridize to the primers or probes used and similarly enzymes can exhibit biases toward certain sequences. This ultimately relies on the access to the target site and folding. For microarrays, this bias may occur at the RNA labeling step. Newly developed microarrays have aimed to eliminate some of these issues by using a label-free system⁵⁸. Although the hybridization efficiency may introduce bias, the preferential binding of specific sequences and associated error likely exists for all platforms. This is especially true when universal array conditions are applied since the optimal conditions of specific probes may be compromised. It is therefore possible that some miRNAs may be left out of analysis if optimal binding does not occur.

Profiling pitfalls can also occur with the use of universal annealing temperatures, primer efficiency and qPCR cycling conditions. Comparing large numbers of miRNAs can introduce T_m issues since miRNAs can vary highly in their GC content and therefore the T_m may differ, leading to complications in primer design. We have seen the same bias in targeted NextGen sequencing, where a GC content >65% yielded a >1 log decrease in coverage. This may be acceptable for resequencing, but would distort any NextGen sequencing based quantification. The primer and probe design can also be complicated by size. Due to the small size of miRNAs, primers must utilize nearly the entire miRNA sequence. Stem-loop RT primers, as opposed to universal RT primers, are long oligos that bind the stem-loop region of the microRNA and contain a region complementary to the sequence of each specific microRNA. The use of these stem-loop primers increases primer specificity while the incorporation of modified oligonucleotides such as locked nucleic acids (or LNAs) can help the issue of T_m variation. Finally, since qPCR primers can form primer dimers and lead to false positive results, it can prove useful to confirm PCR products via gel electrophoresis. While electrophoresis may not distinguish one amplified miRNA from another due to size similarity, it can boost confidence in results by eliminating potential false positives.

Variation among commercial platforms

There are two distinct priming methods used among commercially available qPCR-based platforms. Some platforms make use of unique, sequence-specific RT primers for cDNA synthesis while others make cDNA using universal tailing primers. The universal tailing system used by the Qiagen™, Exiqon™ and SABioscience™ platforms, uses a polyadenylase to generate poly-A tails and an anchored poly-T primer to generate cDNA⁸³. The stem-loop RT primers such as the Applied Biosystems (ABI) Taqman™ primers use a sequence-specific looped RT primer. In our hands, this results in enhanced specificity and sensitivity compared to the conventional linear RT primers.

We directly compared two platforms -- one universal tailing primer platform and one sequence-specific stem-loop primer platform. While the CT data generated from the qPCR correlated rather well, gel electrophoresis analysis of the PCR products using the Caliper™ Labchip GX system revealed a large degree of variation in product size, indicative of non-specific priming (Figure 4). We compared the ten most highly expressed miRNAs to those that were expressed at moderate levels or whose expression levels were undetectable. We observed that the specificity of the sequence-specific RT primers was greatly increased and yielded one prominent PCR product (Figure 4). This was evident for both highly abundant (A) and moderately abundant (B) miRNAs. The sequence-specific RT primer assay failed to yield a signal (CT) for low abundance miRNAs (C). By contrast, the universal tailing RT-primer-based assay yielded a quantitative signal (present call), but most of this signal was due to non-specific amplification. Thus, one can expect a large number of false positive results for this assay. Figure 4 also shows that the most highly expressed miRNAs were not always consistent between platforms due to differences in the workflow of these two commercially available miRNA assays.

Each system, however, has its advantages and drawbacks. The use of unique RT primers can be more time-consuming than the alternate universal method since each miRNA has a specific RT and qPCR primer and probe. In an attempt to eliminate this time constraint, ABI recently introduced pooled RT primers that contain a mixture of these stem-loop primer sequences and decrease the number of sequence-specific reactions needed. Exiqon™, which uses a single universal RT primer, has enhanced the specificity and selectivity of their qPCR primers compared to other assays by incorporating locked nucleotide acid analogs (LNAs)⁹⁶.

The method of priming can affect both the overall detection and the degree of sensitivity to sequence alterations at miRNA ends. In this case, platforms like Exiqon™ display an advantage in detecting isomiRNAs because unlike the unique, stem-loop primers, it does not rely on the 3' end sequence for primer annealing⁸³. Rather, the 5' sequence of the miRNA (first 15- 20nts) influences primer design since shorter primers can be made with LNA technology. Problems with cross-priming can also lead to specificity issues and make it difficult to discriminate between closely related miRNAs. This is especially troubling when trying to detect the expression of miRNAs that belong to the same family and may only differ by 1-3 nucleotides. Unlike qPCR, hybridization-based microarrays do not offer the option of post-assay QC to verify the identity of the hybridized molecule. Moreover, many miRNAs exhibit a high degree of species conservation and therefore some cross-species reactivity will occur. In most cases, the addition of LNAs and sequence-specific primers can both be helpful in boosting assay sensitivity.

Another factor for consideration in data interpretation is qPCR efficiency. The qPCR efficiency can vary due to a number of different reaction parameters including sample concentration, degradation, dyes, non-specific products and the presence of PCR inhibitors or enhancers. Ideally, the efficiency of the qPCR reaction should be 100%, which translates

to a doubling of the PCR product with each cycle. This would result in a 10-fold increase every 3.3 cycles. However, if a particular primer is performing at only 70% efficiency or the efficiency is slightly variable between two samples, the true differences may be vastly different⁹⁷. If variation in PCR efficiency occurs between different samples, it would be reflected in the respective standard curves and cause the slope to vary. Calculation of expression levels based on these standard curve equations would therefore be skewed without also factoring in the PCR efficiency. Therefore, it is important to test the efficiency of the qPCR reaction by performing serial dilutions of known templates to estimate the efficiency differences based on the template, primers, cycling parameters and reaction chemistry. There are several publications and online resources available dedicated to this issue [⁹⁷⁻⁹⁹ <http://www.gene-quantification.de/efficiency.html>].

Normalization of qPCR Data

MiRNAs represent only a small fraction of the total RNA and this fraction can easily vary across samples. Since changes in miRNA expression can be clinically or biologically significant, normalization of data is one of the most important and challenging issues faced when profiling. Cell number cannot really be used as a normalization factor when dealing with tissue samples and normalizing to 18/28S ribosomal RNA (rRNA) can present a challenge for miRNA-enriched samples, where rRNA is absent. Some of the characteristics of a good normalizer are as follows: invariant expression across all samples, expression of the normalizer with target in the cells of interest, high stability in storage conditions, efficiency of extraction and quantification is similar to the target of interest^{95, 100, 101}. Normalizing to a housekeeping gene can remove differences due to sampling, input and quality of RNA and can identify true changes in gene expression.

Currently, many groups use other noncoding RNAs as normalizers for miRNA expression. These may not serve as great reference genes because small nuclear RNAs like U6 do not share the same properties as miRNAs in terms of their transcription, processing and tissue-specific expression patterns. Therefore, especially in experiments analyzing potential defects in miRNA processing and regulation, other small RNAs could be misleading as reference genes. Some miRNAs exhibit stable expression under different conditions and may serve as miRNA reference genes that are good alternatives to U6¹⁰¹. However, the best way to approach analysis of miRNA expression data is through global mean normalization of a set of reference genes. These may be tissue-specific. This method takes a minimum of three stable housekeeping genes and takes the geometric mean to provide a reliable normalization factor that can control for outliers and differences in abundance between genes^{95, 100, 101}.

In addition to reference genes, it is also important to include plate normalizing factors to account for potential plate or slide variation that may arise from pipetting errors and different lot numbers of arrays. Microarray normalization of fluorescent spot intensity can also exhibit variation due to background fluorescence correction and spot quality¹⁰². Although there are several factors to consider for normalization of qPCR and microarray experiments, these methods have been around longer and have undergone several rounds of quality control and optimization, making them an attractive platform for measuring miRNA expression.

Applications and Experimental Design

qPCR-based miRNA profiling can be used with many different sample types and is especially useful when sample is very limited (<50ng). This can be a great way to determine the known miRNA profile of a specific disease or cell type. However, newly identified miRNAs may not be available for profiling use since the throughput of qPCR is lagging behind the growing number of miRBase entries⁴⁻⁶.

One important factor to be considered in experimental design is the potential difference in tissue and cell-type expression levels. Specific microRNAs may be restricted in expression to specific cell types and tissues and this could contribute to differences in microRNA profiling data between different samples. Moreover, in addition to cell-type specific miRNA expression, the mRNA targets may vary between cell or tissue type¹⁰³. One may also find that tissue culture-adapted cell lines have lower variability due to their clonal nature and may differ in expression compared to primary cells.

Several databases including miRanda (microRNA.org) provide expression profiles for miRNAs that can be accessed prior to experimental design. Cell type-specific miRNAs can be helpful to include in profiling studies as controls for confirming cell or tissue type differences. It is important to note that some miRNAs that are “tissue-specific” may not be completely absent and can still be expressed at low levels in other tissues but present at much higher levels in certain tissues or cell types. Since qPCR displays very high sensitivity, it also may be able to detect miRNAs that are present at very low levels that other techniques could deem undetectable. In this case, it is up to the user to determine how physiologically relevant the data is by possibly confirming the results with other techniques. Finally, it is of utmost importance that qPCR-based profiling be performed in several replicates to ensure high confidence in miRNA expression data. While technical replicates can be useful, they are not independent samples and therefore do not increase the number of biological observations of a given subpopulation. Only true biological replicates increase the statistical power of the study.

Platform-specific concerns: Next Generation Sequencing

The use of Next Generation sequencing to analyze gene expression has grown rapidly due to its comprehensive nature. Sequencing can provide information about both known and novel miRNAs, giving it an advantage over techniques that depend on known sequences for assay design. However, there are issues that must be taken into consideration prior to performing your experiment¹⁰⁴. Sequencing can introduce errors during library preparation and may also be contaminated with RNA degradation products, creating elevated noise as compared with other platforms.

The sequencing platform can easily detect sequence variation of miRNAs, expression levels of other members of the small RNA repertoire and post-transcriptional modifications of these small RNAs, providing a more complete picture of a given sample. High-throughput sequencing is also the best way to discover novel miRNAs. However, much more work is required to confirm novel miRNAs than solely the detection of reads. A recent sequencing study found that a considerable proportion of newly identified miRNAs could merely be artifacts¹⁰⁵.

Another advantage of the sequencing platform for miRNA profiling is the large dynamic range provided by this technique if enough input is available. Sequencing can detect above five orders of magnitude dynamic range although its 95% confidence interval is actually similar to that of the microarray^{51, 56, 60, 106}. Like other techniques, several versions of sequencing platforms exist and platforms vary based on the desired read length. The Roche 454 sequencing system provides the user with longer reads of about 400bp but the overall number of reads tends to be lower (~400,000/sample). Other systems such as Solexa (Illumina) and SOLiD (ABI) output a higher number of shorter reads (~35bp reads and up to 100 million reads/sample). Both of these techniques have proved efficient for assessing microRNA expression^{18, 23, 25, 26, 29, 31, 70, 81, 83, 106, 107}. A high correlation between the different sequencing platforms has been observed and there seems to be less variation here as compared with the different commercially available qPCR and microarray assays^{51, 106}.

Experimental Preparation

Several sources of bias can emerge during sample preparation for sequencing. First, RNA quality should be tested prior to proceeding with the experiment although miRNAs can exhibit high stability. The most commonly observed problems with sample preparation involve the introduction of RNA degradation products, contamination of the sample with ribosomal RNA and adapter and enzyme bias. Factors such as the preferential ligation of adapters or barcodes to RNA containing certain sequences and variation in enzymatic efficiency can generate bias during library preparation. Also, since the library undergoes both a reverse transcription and PCR amplification step prior to sequencing, some of the same biases discussed earlier may be introduced and amplified during this time¹⁰⁸. The assay reproducibility may ultimately depend on the consistency of the preparation method and the quality of RNA sample input. Spiked-in oligonucleotides of known concentrations can also be added to samples prior to sequencing preparation to help track and quantify sample input lost during the technique, detect any potential sequencing errors and assess other factors that can affect the data during experimental library preparation. Moreover, since Next Generation sequencing is fairly novel, the introduction of newer products aiming to eliminate biases such as ribosomal RNA contamination will improve sequencing as a reliable miRNA profiling platform.

Applications

Next Generation sequencing has many applications. In terms of miRNA profiling, it provides a broad picture of the small RNA profile. Sequencing is not restricted to detecting the expression of known miRNAs and exhibits the highest discerning power for identifying unknown, novel miRNAs. In addition to discovery, this technique can be applied to detect different isoforms of miRNAs, new sequence variants and other types of small RNAs such as mirtrons, shRNAs, piwi-interacting RNAs or degradation pathway intermediates. Therefore, if one is interested in more broad-based profiling or obtaining data on different classes of small RNAs, sequencing is the best profiling platform.

Deep sequencing techniques have been used to profile and identify both viral and cellular miRNAs in response to infection with many different viruses such as the herpesviruses EBV, KSHV, MHV68, Marek's disease virus, HCV, Avian Influenza, rLCV and Adenovirus^{9, 10, 17-21, 23, 25, 26, 29, 31, 33}. These studies have provided insight into how miRNAs may control the lifecycle and pathogenesis of virus-associated diseases. One study using sequence-based profiling of small RNAs revealed that miRNAs, newly identified miRNA offset RNAs (moRNAs) and antisense miRNAs (as-miRNAs) are all expressed following infection with Kaposi's sarcoma-associated herpesvirus (KSHV), leaving us with a much more complete picture of virus-induced changes in the small RNA repertoire¹⁸. Furthermore, these types of studies have contributed important information to the field of small RNAs as a whole. High throughput sequencing-based miRNA profiling will continue to grow as a field and shed light on various aspects of miRNA expression, function and processing.

After performing sequencing, there is a need to further evaluate the noncoding transcripts detected to ensure that they are functionally relevant and do not just appear due to technical noise. MicroRNA sequencing data can be confirmed by Northern blot analysis and also by confirming the alignment of the sequence reads with the pre-microRNA stem-loop region in the reference genome. When examining both viral and host miRNAs within infected cells, an important factor in experimental design is the percent of infection or transformation as it can affect the proportion of sequencing reads mapping to viral miRNAs. Another area of caution is the discovery of novel miRNAs. For miRNA discovery, computational predictions alone are not robust enough and they can lead to false positive results. However, novel viral

and cellular miRNAs can be predicted using computational strategies and then experimentally confirmed by several other methods. One such prediction database for viral miRNAs is vir-mir db, a database that predicts miRNA hairpin loops based on virus sequence and secondary structure²⁸. Predictions from online databases or computational programs can then be mapped to small RNA reads for alignment. One potential caveat in attempting discovery in this manner is that the 5' end of predicted miRNAs or stemloop regions might not be precise due to false prediction algorithms or miRNA editing events. For other experimental methods and criteria regarding new miRNAs, researchers are encouraged to examine the new criteria for miRNA discovery referenced here¹⁰⁵.

Sensitivity

While deep sequencing may capture non-specific fragments such as degradation products, its high sensitivity can be of great experimental use. First of all, miRNAs that are undetectable by Northern blotting or microarray may produce low levels of count data from sequencing. The question that arises: What is the biological relevance of the low-abundance miRNA? The high sensitivity of Next Generation sequencing also allows identification of potential disease-specific mutations within the miRNA transcriptome, which can correlate and sometimes predict disease progression or outcome^{9, 10}. Other techniques such as qPCR-based profiling, while sensitive, may detect, but not identify these SNPs since mutations inhibit the primers from binding or yield an altered melting profiling to the mutated miRNA.

Bioinformatics and Analysis

Analysis of sequencing data is complex, requires in-depth bioinformatics and complicated sequence algorithms. In addition to its long runtime, sequencing may require more time for analysis and in some cases extra personnel with expertise in statistical analysis of this type of data. While more user-friendly programs are being introduced for this growing field, sequencing can provide an overwhelming amount of read data that can be difficult to decode and translate into miRNA profiles¹⁰⁷. Moreover, the different statistical analysis methods may alter the classification and clustering of sequencing samples (our data, Lee et al, submitted). A reliable standard approach has yet to emerge.

Sequencing read data is typically first aligned to known miRNAs registered in miRBase or to the organism being studied. However, introduction of bias due to RNA ligase preferences, the cDNA synthesis reaction and PCR amplification of libraries may cause problems with normalization. One can try scaling the data to the size of the library and report the reads of a particular miRNA over the total number of aligned reads as a fraction of the miRNA profile. The use of spike-in oligonucleotides may also be helpful in normalizing the data. Universal reference miRNAs are also currently in development to aid in the process of normalizing complex sequencing data^{109, 110}.

Pre-miRNAs as disease markers

In addition to analyzing the mature miRNA repertoire, precursor miRNA (pre-miRNA) profiling has also been used successfully to delineate stages of cellular transformation and disease¹². Expression levels of these stem-loop precursors can be analyzed using Next Generation sequencing of small RNAs or qPCR-based assays^{18, 21, 40, 93}. Pre-miRNAs can offer several technical advantages in terms of profiling and are similar in this respect to mRNAs. Their increased length (~70nt) allows for better primer design and enhanced assay specificity. Also, because they represent an intermediate of miRNA processing, pre-miRNAs may offer a more robust and quick response to changes in cellular transcription (Figure 1). In addition, their decreased stability may also increase assay sensitivity for profiling various types of samples. One of the limitations of pre-miRNA profiling is that

differences in miRNA processing and maturation may not be evident until it reaches the mature miRNA stage and modifications of pre-microRNAs can be tissue-specific¹¹¹. Consequently, although pre-miRNAs often correlate with the levels of mature miRNAs, profiling of both the precursor and mature species can provide non-redundant information for classifying samples into distinct and biologically relevant clusters. These two assays perform with slightly different characteristics and therefore one may detect a change the other cannot. Therefore, combining pre-miR and mature miRNA profiling can provide a more complete picture of the response to disease, viral infection and other cellular stresses.

Conclusion

MiRNA profiling provides valuable information on the expression levels and kinetics of these small RNAs and may reflect onto their potential biological roles in normal cellular function and disease. We have taken an in-depth look at several profiling techniques and visited the advantages and potential pitfalls of each. The best microRNA profiling platform may ultimately be determined by the convenience, dynamic range, variability or experience with a particular technique as well as local availability and cost. Any platform that is well tested in your experimental system and displays low technical variance will likely be an effective way of examining the small RNA repertoire. Once a primary profiling technique is chosen, it is advisable to avoid switching between platforms and preparatory reagents to achieve the best consistency among results. Confirmation of results using alternate methods such as qPCR or Northern blotting is also important. Furthermore, modulation of miRNA expression levels by addition of commercially available mimics and miRNA hairpin inhibitors allow researchers to explore the potential importance and function of a given miRNA signature.

Acknowledgments

This work is supported by NIH grant CA019014 to DPD. PC is a recipient of a T32 award T32- CA009156-37.

References

1. Sun G, Li H, Rossi JJ. Sequence context outside the target region influences the effectiveness of miR-223 target sites in the RhoB 3' UTR. *Nucleic Acids Res.* Jan; 2010 38(1):239–252. [PubMed: 19850724]
2. Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. *PLoS Biol.* Mar.2005 3(3):e85. [PubMed: 15723116]
3. Didiano D, Hobert O. Perfect seed pairing is not a generally reliable predictor for miRNA-target interactions. *Nat Struct Mol Biol.* Sep; 2006 13(9):849–851. [PubMed: 16921378]
4. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. *Nucleic Acids Res.* Jan 1; 2006 34(Database issue):D140–144. [PubMed: 16381832]
5. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. *Nucleic Acids Res.* Jan; 2008 36(Database issue):D154–158. [PubMed: 17991681]
6. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. *Nucleic Acids Res.* Jan; 2011 39(Database issue):D152–157. [PubMed: 21037258]
7. Griffiths-Jones S. The microRNA Registry. *Nucleic Acids Res.* Jan 1; 2004 32(Database issue):D109–111. [PubMed: 14681370]
8. Gottwein E, Cai X, Cullen BR. A novel assay for viral microRNA function identifies a single nucleotide polymorphism that affects Drosha processing. *J Virol.* Jun; 2006 80(11):5321–5326. [PubMed: 16699012]
9. Marshall V, Martro E, Labo N, et al. Kaposi sarcoma (KS)-associated herpesvirus microRNA sequence analysis and KS risk in a European AIDS-KS case control study. *J Infect Dis.* Oct 1; 2010 202(7):1126–1135. [PubMed: 20715927]

10. Marshall V, Parks T, Bagni R, et al. Conservation of virally encoded microRNAs in Kaposi sarcoma-associated herpesvirus in primary effusion lymphoma cell lines and in patients with Kaposi sarcoma or multicentric Castleman disease. *J Infect Dis.* Mar 1; 2007 195(5):645–659. [PubMed: 17262705]
11. Lei X, Bai Z, Ye F, et al. Regulation of NF-kappaB inhibitor IkappaBalpha and viral replication by a KSHV microRNA. *Nat Cell Biol.* Feb; 2010 12(2):193–199. [PubMed: 20081837]
12. O'Hara AJ, Chugh P, Wang L, et al. Pre-micro RNA signatures delineate stages of endothelial cell transformation in Kaposi sarcoma. *PLoS Pathog.* Apr. 2009 5(4):e1000389. [PubMed: 19381257]
13. Hansen A, Henderson S, Lagos D, et al. KSHV-encoded miRNAs target MAF to induce endothelial cell reprogramming. *Genes Dev.* Jan 15; 2010 24(2):195–205. [PubMed: 20080955]
14. Lu F, Stedman W, Yousef M, Renne R, Lieberman PM. Epigenetic regulation of Kaposi's sarcoma-associated herpesvirus latency by virus-encoded microRNAs that target Rta and the cellular Rbl2-DNMT pathway. *J Virol.* Mar; 2010 84(6):2697–2706. [PubMed: 20071580]
15. Qin Z, Freitas E, Sullivan R, et al. Upregulation of xCT by KSHV-encoded microRNAs facilitates KSHV dissemination and persistence in an environment of oxidative stress. *PLoS Pathog.* Jan. 2010 6(1):e1000742. [PubMed: 20126446]
16. Boss IW, Renne R. Viral miRNAs and immune evasion. *Biochim Biophys Acta.* Nov; 2011 1809(11-12):708–714. [PubMed: 21757042]
17. Chandriani S, Xu Y, Ganem D. The lytic transcriptome of Kaposi's sarcoma-associated herpesvirus reveals extensive transcription of noncoding regions, including regions antisense to important genes. *J Virol.* Aug; 2010 84(16):7934–7942. [PubMed: 20534856]
18. Lin YT, Kincaid RP, Arasappan D, Dowd SE, Hunnicke-Smith SP, Sullivan CS. Small RNA profiling reveals antisense transcription throughout the KSHV genome and novel small RNAs. *RNA.* Aug; 2010 16(8):1540–1558. [PubMed: 20566670]
19. Pfeffer S, Sewer A, Lagos-Quintana M, et al. Identification of microRNAs of the herpesvirus family. *Nat Methods.* Apr; 2005 2(4):269–276. [PubMed: 15782219]
20. Rachamadugu R, Lee JY, Wooming A, Kong BW. Identification and expression analysis of infectious laryngotracheitis virus encoding microRNAs. *Virus Genes.* Dec; 2009 39(3):301–308. [PubMed: 19728068]
21. Riley KJ, Rabinowitz GS, Steitz JA. Comprehensive analysis of Rhesus lymphocryptovirus microRNA expression. *J Virol.* May; 2010 84(10):5148–5157. [PubMed: 20219930]
22. Xu H, Yao Y, Zhao Y, Smith LP, Baigent SJ, Nair V. Analysis of the expression profiles of Marek's disease virus-encoded microRNAs by real-time quantitative PCR. *J Virol Methods.* May; 2008 149(2):201–208. [PubMed: 18355930]
23. Zhu JY, Strehle M, Frohn A, et al. Identification and analysis of expression of novel microRNAs of murine gammaherpesvirus 68. *J Virol.* Oct; 2010 84(19):10266–10275. [PubMed: 20668074]
24. Chendrimada TP, Gregory RI, Kumaraswamy E, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. *Nature.* Aug 4; 2005 436(7051):740–744. [PubMed: 15973356]
25. Cui L, Guo X, Qi Y, et al. Identification of microRNAs involved in the host response to enterovirus 71 infection by a deep sequencing approach. *J Biomed Biotechnol.* 2010; 2010:425939. [PubMed: 20625495]
26. Kong BW. Identification of virus encoding microRNAs using 454 FLX sequencing platform. *Methods Mol Biol.* 2011; 733:81–91. [PubMed: 21431764]
27. Li LM, Hu ZB, Zhou ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. *Cancer Res.* Dec 1; 2010 70(23):9798–9807. [PubMed: 21098710]
28. Li SC, Shiau CK, Lin WC. Vir-Mir db: prediction of viral microRNA candidate hairpins. *Nucleic Acids Res.* Jan; 2008 36(Database issue):D184–189. [PubMed: 17702763]
29. Qi Y, Tu J, Cui L, et al. High-throughput sequencing of microRNAs in adenovirus type 3 infected human laryngeal epithelial cells. *J Biomed Biotechnol.* 2010; 2010:915980. [PubMed: 20634878]
30. Sullivan CS, Sung CK, Pack CD, et al. Murine Polyomavirus encodes a microRNA that cleaves early RNA transcripts but is not essential for experimental infection. *Virology.* Apr 25; 2009 387(1):157–167. [PubMed: 19272626]

31. Umbach JL, Cullen BR. In-depth analysis of Kaposi's sarcoma-associated herpesvirus microRNA expression provides insights into the mammalian microRNA-processing machinery. *J Virol.* Jan; 2010 84(2):695–703. [PubMed: 19889781]
32. Varnholt H, Drebber U, Schulze F, et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. *Hepatology.* Apr; 2008 47(4):1223–1232. [PubMed: 18307259]
33. Wang Y, Brahmakshatriya V, Zhu H, et al. Identification of differentially expressed miRNAs in chicken lung and trachea with avian influenza virus infection by a deep sequencing approach. *BMC Genomics.* 2009; 10:512. [PubMed: 19891781]
34. Witwer KW, Sarbanes SL, Liu J, Clements JE. A plasma microRNA signature of acute lentiviral infection: biomarkers of central nervous system disease. *AIDS.* Nov 13; 2011 25(17):2057–2067. [PubMed: 21857495]
35. Wong AM, Kong KL, Tsang JW, Kwong DL, Guan XY. Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. *Cancer.* Jun 30.2011
36. Zhou J, Yu L, Gao X, et al. Plasma MicroRNA Panel to Diagnose Hepatitis B Virus-Related Hepatocellular Carcinoma. *J Clin Oncol.* Nov 21.2011
37. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc Natl Acad Sci U S A.* Mar 22; 2011 108(12):5003–5008. [PubMed: 21383194]
38. Chang J, Nicolas E, Marks D, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. *RNA Biol.* Jul; 2004 1(2):106–113. [PubMed: 17179747]
39. Kuchenbauer F, Morin RD, Argiropoulos B, et al. In-depth characterization of the microRNA transcriptome in a leukemia progression model. *Genome Res.* Nov; 2008 18(11):1787–1797. [PubMed: 18849523]
40. O'Hara AJ, Vahrson W, Dittmer DP. Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma. *Blood.* Feb 15; 2008 111(4):2347–2353. [PubMed: 18079361]
41. Wang LG, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. *Cancer Epidemiol.* Oct 20.2011
42. Wei J, Gao W, Zhu CJ, et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. *Chin J Cancer.* Jun; 2011 30(6):407–414. [PubMed: 21627863]
43. Zhang Y, Jia Y, Zheng R, et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. *Clin Chem.* Dec; 2010 56(12):1830–1838. [PubMed: 20930130]
44. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. *Cell.* Oct 17; 2003 115(2):209–216. [PubMed: 14567918]
45. Tomari Y, Matranga C, Haley B, Martinez N, Zamore PD. A protein sensor for siRNA asymmetry. *Science.* Nov 19; 2004 306(5700):1377–1380. [PubMed: 15550672]
46. Maniatakis E, Mourelatos Z. A human, ATP-independent, RISC assembly machine fueled by pre-miRNA. *Genes Dev.* Dec 15; 2005 19(24):2979–2990. [PubMed: 16357216]
47. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in *Drosophila* cells. *Nature.* Mar 16; 2000 404(6775):293–296. [PubMed: 10749213]
48. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. *Cell.* Oct 17; 2003 115(2):199–208. [PubMed: 14567917]
49. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. *Nucleic Acids Res.* 2005; 33(20):e179. [PubMed: 16314309]
50. Kauppinen S, Vester B, Wengel J. Locked nucleic acid: high-affinity targeting of complementary RNA for RNomics. *Handb Exp Pharmacol.* 2006; (173):405–422. [PubMed: 16594628]
51. Sato F, Tsuchiya S, Terasawa K, Tsujimoto G. Intra-platform repeatability and inter-platform comparability of microRNA microarray technology. *PLoS One.* 2009; 4(5):e5540. [PubMed: 19436744]

52. Jang JS, Simon VA, Feddersen RM, et al. Quantitative miRNA expression analysis using fluidigm microfluidics dynamic arrays. *BMC Genomics*. 2011; 12:144. [PubMed: 21388556]
53. Moltzahn F, Olshen AB, Baehner L, et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. *Cancer Res*. Jan 15; 2011 71(2):550–560. [PubMed: 21098088]
54. White AK, VanInsberghe M, Petriv OI, et al. High-throughput microfluidic single-cell RT-qPCR. *Proc Natl Acad Sci U S A*. Aug 23; 2011 108(34):13999–14004. [PubMed: 21808033]
55. Liu CG, Calin GA, Meloon B, et al. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. *Proc Natl Acad Sci U S A*. Jun 29; 2004 101(26):9740–9744. [PubMed: 15210942]
56. Liu CG, Calin GA, Volinia S, Croce CM. MicroRNA expression profiling using microarrays. *Nat Protoc*. 2008; 3(4):563–578. [PubMed: 18388938]
57. Liu CG, Spizzo R, Calin GA, Croce CM. Expression profiling of microRNA using oligo DNA arrays. *Methods*. Jan; 2008 44(1):22–30. [PubMed: 18158129]
58. Duan D, Zheng KX, Shen Y, et al. Label-free high-throughput microRNA expression profiling from total RNA. *Nucleic Acids Res*. Oct 5.2011
59. Miska EA, Alvarez-Saavedra E, Townsend M, et al. Microarray analysis of microRNA expression in the developing mammalian brain. *Genome Biol*. 2004; 5(9):R68. [PubMed: 15345052]
60. Nelson PT, Baldwin DA, Scarce LM, Oberholtzer JC, Tobias JW, Mourelatos Z. Microarray-based, high-throughput gene expression profiling of microRNAs. *Nat Methods*. Nov; 2004 1(2): 155–161. [PubMed: 15782179]
61. Stahlberg A, Kubista M, Pfaffl M. Comparison of reverse transcriptases in gene expression analysis. *Clin Chem*. Sep; 2004 50(9):1678–1680. [PubMed: 15331507]
62. Wang Y, Zheng D, Tan Q, Wang MX, Gu LQ. Nanopore-based detection of circulating microRNAs in lung cancer patients. *Nat Nanotechnol*. Oct; 2011 6(10):668–674. [PubMed: 21892163]
63. Wanunu M, Dadosh T, Ray V, Jin J, McReynolds L, Drndic M. Rapid electronic detection of probe-specific microRNAs using thin nanopore sensors. *Nat Nanotechnol*. Nov; 2010 5(11):807–814. [PubMed: 20972437]
64. Bayley H, Jayasinghe L. Functional engineered channels and pores (Review). *Mol Membr Biol*. Jul; 2004 21(4):209–220. [PubMed: 15371010]
65. Gu LQ, Shim JW. Single molecule sensing by nanopores and nanopore devices. *Analyst*. Mar; 2010 135(3):441–451. [PubMed: 20174694]
66. Howorka S, Siwy Z. Nanopore analytics: sensing of single molecules. *Chem Soc Rev*. Aug; 2009 38(8):2360–2384. [PubMed: 19623355]
67. Movileanu L. Interrogating single proteins through nanopores: challenges and opportunities. *Trends Biotechnol*. Jun; 2009 27(6):333–341. [PubMed: 19394097]
68. Ma L, Cockroft SL. Biological nanopores for single-molecule biophysics. *Chembiochem*. Jan 4; 2010 11(1):25–34. [PubMed: 19938028]
69. Baker M. MicroRNA profiling: separating signal from noise. *Nat Methods*. Sep; 2010 7(9):687–692. [PubMed: 20805796]
70. Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. *Cell*. Jun 29; 2007 129(7):1401–1414. [PubMed: 17604727]
71. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. *Proc Natl Acad Sci U S A*. Mar 1; 2011 108(9):3713–3718. [PubMed: 21300873]
72. Cortez MA, Calin GA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. *Expert Opin Biol Ther*. Jun; 2009 9(6):703–711. [PubMed: 19426115]
73. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). *Methods*. Apr; 2010 50(4):298–301. [PubMed: 20146939]

74. Baccarini A, Chauhan H, Gardner TJ, Jayaprakash AD, Sachidanandam R, Brown BD. Kinetic analysis reveals the fate of a microRNA following target regulation in mammalian cells. *Curr Biol*. Mar 8; 2011 21(5):369–376. [PubMed: 21353554]
75. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. *Nature*. Sep 4; 2008 455(7209):64–71. [PubMed: 18668037]
76. Brown BD, Gentner B, Cantore A, et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. *Nat Biotechnol*. Dec; 2007 25(12):1457–1467. [PubMed: 18026085]
77. Brown BD, Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. *Nat Rev Genet*. Aug; 2009 10(8):578–585. [PubMed: 19609263]
78. Haley B, Zamore PD. Kinetic analysis of the RNAi enzyme complex. *Nat Struct Mol Biol*. Jul; 2004 11(7):599–606. [PubMed: 15170178]
79. Hutvagner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. *Science*. Sep 20; 2002 297(5589):2056–2060. [PubMed: 12154197]
80. Selbach M, Schwanhaussner B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. *Nature*. Sep 4; 2008 455(7209):58–63. [PubMed: 18668040]
81. Morin RD, O'Connor MD, Griffith M, et al. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. *Genome Res*. Apr; 2008 18(4):610–621. [PubMed: 18285502]
82. Ebhardt HA, Fedynak A, Fahlman RP. Naturally occurring variations in sequence length creates microRNA isoforms that differ in argonaute effector complex specificity. *Silence*. 2010; 1(1):12. [PubMed: 20534119]
83. Lee LW, Zhang S, Etheridge A, et al. Complexity of the microRNA repertoire revealed by next-generation sequencing. *RNA*. Nov; 2010 16(11):2170–2180. [PubMed: 20876832]
84. Wu H, Ye C, Ramirez D, Manjunath N. Alternative processing of primary microRNA transcripts by Drosha generates 5' end variation of mature microRNA. *PLoS One*. 2009; 4(10):e7566. [PubMed: 19859542]
85. Ebhardt HA, Tsang HH, Dai DC, Liu Y, Bostan B, Fahlman RP. Meta-analysis of small RNA-sequencing errors reveals ubiquitous post-transcriptional RNA modifications. *Nucleic Acids Res*. May; 2009 37(8):2461–2470. [PubMed: 19255090]
86. Yang W, Chendrimada TP, Wang Q, et al. Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. *Nat Struct Mol Biol*. Jan; 2006 13(1):13–21. [PubMed: 16369484]
87. Ehrenreich IM, Purugganan MD. Sequence variation of MicroRNAs and their binding sites in *Arabidopsis*. *Plant Physiol*. Apr; 2008 146(4):1974–1982. [PubMed: 18305205]
88. Seitz H, Ghildiyal M, Zamore PD. Argonaute loading improves the 5' precision of both MicroRNAs and their miRNA* strands in flies. *Curr Biol*. Jan 22; 2008 18(2):147–151. [PubMed: 18207740]
89. Kai ZS, Pasquinelli AE. MicroRNA assassins: factors that regulate the disappearance of miRNAs. *Nat Struct Mol Biol*. Jan; 2010 17(1):5–10. [PubMed: 20051982]
90. Tseng GC, Oh MK, Rohlin L, Liao JC, Wong WH. Issues in cDNA microarray analysis: quality filtering, channel normalization, models of variations and assessment of gene effects. *Nucleic Acids Res*. Jun 15; 2001 29(12):2549–2557. [PubMed: 11410663]
91. Moltzahn F, Hunkapiller N, Mir AA, Imbar T, Blemloch R. High throughput microRNA profiling: optimized multiplex qRT-PCR at nanoliter scale on the fluidigm dynamic array™ IFCs. *J Vis Exp*. 2011; (54)
92. Zhou X, Zhu Q, Eicken C, et al. MicroRNA Profiling Using microParaflo Microfluidic Array Technology. *Methods Mol Biol*. 2012; 822:153–182. [PubMed: 22144198]
93. Chugh P, Tamburro K, Dittmer DP. Profiling of pre-micro RNAs and microRNAs using quantitative real-time PCR (qPCR) arrays. *J Vis Exp*. 2010; (46)
94. Kitchen RR, Kubista M, Tichopad A. Statistical aspects of quantitative real-time PCR experiment design. *Methods*. Apr; 2010 50(4):231–236. [PubMed: 20109551]

95. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol.* Jun 18.2002 3(7) RESEARCH0034.
96. Kore AR, Hodeib M, Hu Z. Chemical Synthesis of LNA-mCTP and its application for MicroRNA detection. *Nucleosides Nucleotides Nucleic Acids.* Jan; 2008 27(1):1–17. [PubMed: 18188765]
97. Lock EF, Ziemiecke R, Marron J, Dittmer DP. Efficiency clustering for low-density microarrays and its application to QPCR. *BMC Bioinformatics.* 2010; 11:386. [PubMed: 20646303]
98. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. *Nucleic Acids Res.* May 1.2002 30(9):e36. [PubMed: 11972351]
99. Tichopad A, Dilger M, Schwarz G, Pfaffl MW. Standardized determination of real-time PCR efficiency from a single reaction set-up. *Nucleic Acids Res.* Oct 15.2003 31(20):e122. [PubMed: 14530455]
100. Meyer SU, Pfaffl MW, Ulbrich SE. Normalization strategies for microRNA profiling experiments: a ‘normal’ way to a hidden layer of complexity? *Biotechnol Lett.* Dec; 2010 32(12): 1777–1788. [PubMed: 20703800]
101. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. *RNA.* May; 2008 14(5):844–852. [PubMed: 18375788]
102. Yang MC, Ruan QG, Yang JJ, et al. A statistical method for flagging weak spots improves normalization and ratio estimates in microarrays. *Physiol Genomics.* Oct 10; 2001 7(1):45–53. [PubMed: 11595791]
103. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. *Curr Biol.* Apr 30; 2002 12(9):735–739. [PubMed: 12007417]
104. Kircher M, Kelso J. High-throughput DNA sequencing--concepts and limitations. *Bioessays.* Jun; 2010 32(6):524–536. [PubMed: 20486139]
105. Chiang HR, Schoenfeld LW, Ruby JG, et al. Mammalian microRNAs: experimental evaluation of novel and previously annotated genes. *Genes Dev.* May 15; 2010 24(10):992–1009. [PubMed: 20413612]
106. Willenbrock H, Salomon J, Sokilde R, et al. Quantitative miRNA expression analysis: comparing microarrays with next-generation sequencing. *RNA.* Nov; 2009 15(11):2028–2034. [PubMed: 19745027]
107. Wang WC, Lin FM, Chang WC, Lin KY, Huang HD, Lin NS. miRExpress: analyzing high-throughput sequencing data for profiling microRNA expression. *BMC Bioinformatics.* 2009; 10:328. [PubMed: 19821977]
108. Tian G, Yin X, Luo H, et al. Sequencing bias: comparison of different protocols of microRNA library construction. *BMC Biotechnol.* 2010; 10:64. [PubMed: 20815927]
109. Mestdagh P, Van Vlierberghe P, De Weer A, et al. A novel and universal method for microRNA RT-qPCR data normalization. *Genome Biol.* 2009; 10(6):R64. [PubMed: 19531210]
110. Bissels U, Wild S, Tomiuk S, et al. Absolute quantification of microRNAs by using a universal reference. *RNA.* Dec; 2009 15(12):2375–2384. [PubMed: 19861428]
111. Newman MA, Mani V, Hammond SM. Deep sequencing of microRNA precursors reveals extensive 3' end modification. *RNA.* Oct; 2011 17(10):1795–1803. [PubMed: 21849429]




Figure 1. Profiling of miRNAs at various stages provides non-redundant information
 MicroRNA profiling can be performed at several different steps during microRNA biogenesis. The pri-miRNA DNA form can provide insight into deletions and SNP amplifications while the pre-miRNA yields information on the transcriptional regulation of microRNAs. Both of these forms display less stability than the mature microRNA form, which is helpful in obtaining an overall profile of the microRNA repertoire of the cell and can also lead to findings regarding microRNA processing, stability and export. Therefore, profiling of different microRNA forms can yield non-redundant information on the state of microRNA expression in a given cell.




Figure 2. Schematic of the microRNA processing steps that can influence the profile of pri-, pre- and mature microRNAs

The rate of each processing step is denoted by a k value: k_1 - k_6 . Each k value has the potential to affect the turnover and size of the microRNA pool to be analyzed. The different microRNA forms that can be profiled are shown along with their target size, ranging from a large miRNA gene to only 22nt for the mature microRNA. The mature microRNA is the smallest of these and is subject to the greatest amount of processing and therefore can be affected by many k values or processing rates. The opposite is true for the pri-miRNA and microRNA gene (larger size and less influential k values). The pri-miRNA can provide insight into microRNA regulation whereas the mature form gives data more relevant to microRNA function.




Figure 3. Dominant isomiRNAs of KSHV K12-2 are revealed by NextGen sequencing

Illumina small RNA sequencing data was aligned to the KSHV miR-K12-2 seed sequence for homology. The square root of the frequency of these reads was calculated and is displayed for each isomir matching the KSHV miR-K12-2 seed sequence. Although many isomiRNAs seem to be expressed at relatively low frequencies, two dominant isomiRNAs of KSHV K12-2 emerge and contribute to the majority of the signal detected. The sequences are shown and differ by a single nucleotide in length, characteristic of many isomiRNAs.




Figure 4. Comparison of qPCR-based microRNA profiling reveals differences in target specificity

Two qPCR-based microRNA profiling platforms were tested—one that uses sequence-specific primers for the reverse transcription (RT) reaction and another which uses a universal tailing primer for cDNA synthesis. RT reactions were performed according to each manufacturer’s protocols and the cDNA was used as template for qPCR profiling of microRNAs. For profiling, the corresponding microRNA arrays from each company were run using the appropriate cycling parameters. The top 10 highest, middle 10 and lowest 10 abundant miRNAs were then run on a Caliper LabChipGX gel for further analysis and gel images for both platforms are shown. The top and bottom bands denote the upper and lower markers of the LabChip HT DNA 1k kit and do not correspond to amplified PCR products.

Table 1
Influential Factors in Choosing a MicroRNA Platform

The three major profiling methods and the requirements for performing each are shown. Factors such as runtime, sample input, detection of the dynamic range and issues with analysis are characterized for each method.

Profiling Method	Time	Sample Input	Cost	Dynamic Range	Applications	Analysis
qPCR/ Microfluidics	6 hours	500ng/10ng	\$400	6 orders of magnitude; use of spike-ins of known concentration to detect sample range	High-throughput profiling of known miRs , easy automation; qPCR great for confirmatory assay	Normalization to reference gene expression
Microarray	~2 days	100ng-1 μ g	~\$300	4 orders of magnitude	Profiling known miRs across samples	Normalization to reference gene expression
NextGen Sequencing	1-2 weeks	500ng-5 μ g	\$1000+	5+ orders of magnitude	Different sequencing platforms; profiling, miR discovery and diversity	Potentially large investment in bioinformatic analysis, time and personnel